The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tiziana Life Science PLC (LON:TILS; Nasdaq:TLSA) is worth around 300% more than the current share price based on just two of its potential pipeline developments, according to HC Wainwright.
I think this summary of the HC Wainwright broker target by Proactive might even have a slight effect before the close. Bonkers price being under £1 imho!!!!!!!!
Don't worry Stims, it's coming! It's a pretty complex strategy to implement, lots of areas to cover for this to happen and the world is still emerging from LockDown, Lawyers are the key element for this to keep progressing.
We will get an update next week and then I see this happening in early July, Lock-in period will be some point this Month in order to form part of the process.
Spinoff won't be long...load up all you can before then...I'm hoping it takes another couple of weeks
I did think we'd have heard about the Stemprinter spin off by now. RNS was 2 weeks ago today and Gabrielle referred to it happening "Shortly" in the interview. I take shortly as days or weeks rather than months so hope to hear something very soon.
Locked in more TILS before the weekend!
I see this as a great day to accumulate under £1.
TILS will have it's day very soon.
Good timing so that people can read and soak it all in over the weekend.....then buy.
Just came out, that same broker note. I wish the current price would move in that direction a little .......!
https://www.proactiveinvestors.com/companies/news/921274/tiziana-life-sciences-worth-us25-per-ads-according-to-hc-wainwright-921274.html
The target follows the biotech's recent updates on two projects: foralumab and StemPrintER.
Tiziana Life Science PLC (LON:TLSA Nasdaq:TSLA)) is worth around 300% more than the current share price based on just two of its potential pipeline developments, according to HC Wainwright.
The broker reiterated its US$25 price target and 'buy' rating for the Nasdaq-listed ADS following the biotech's recent updates on two projects: foralumab and StemPrintER.
This target, though excludes any contribution in future from foralumab beyond Crohn's disease or milciclib in cancers beyond HCC (liver); or anything from StemPrintER or TZLS-501 (coronavirus), said the broker.
“Positive clinical data with foralumab for indications representing massive markets like AD (Alzheimer’s) and MS (multiple sclerosis) could thus constitute a considerable upside to our assumptions,” added analyst Raghuram Selvaraju.
Earlier this week, Tiziana reported that Howard Weiner, the chairman of its scientific advisory board, had received a grant from the NIH to investigate foralumab, its nasally delivered anti-CD3 monoclonal antibody (mAb), as a possible Alzheimer's treatment.
The grant followed a demonstration by Weiner that unexpectedly found that the nasally delivered anti-CD3 modulated brain microglia in animal models.
Activated microglia have been shown in studies to essentially 'erase' memories in mice, said Selvaraju.
Tiziana has a worldwide exclusive licence for nasal administration of anti-CD3 mAbs for the treatment of neurodegenerative diseases including Alzheimer’s, noted the analyst, from Brigham and Women’s Hospital, Harvard Medical School, Boston.
Phase I trials have focused on its use as a treatment for multiple sclerosis and Crohn’s disease, respectively, said Selvaraju but plans are in train for phase II studies in both conditions for nasally and orally administered formulations.
Selvaraju expects a proof-of-concept study might start for oral foralumab as a treatment for Crohn’s and intra-nasal foralumab for multiple sclerosis within six to 12 months.
Tiziana is also working on an inhaled form to address lung inflammation and dysfunction in patients infected with the SARS-CoV-2 coronavirus, which is responsible for the COVID-19 pandemic.
On StemPrintER, Selvaraju added that validation data presented at ASCO in posters provided compelling evidence of its predictive power for breast cancer and its superiority over the current standard Oncotype DX.
The shares are trading at 96p in London and US$6.50 in ADS form on Nasdaq